Cost-Effectiveness Analysis of Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in People With Type 2 Diabetes Treated With Non-Intensive Insulin Therapy in South Korea

Objectives: There is limited evidence regarding the cost-effectiveness of real-time continuous glucose monitoring (rt-CGM) in the management of type 2 diabetes in patients receiving basal insulin regimens in South Korea. This study aimed to address this gap by analyzing the cost-effectiveness of rt-CGM when compared with self-monitoring of blood glucose. Research design and methods: The cost-effectiveness of rt-CGM was modeled using the IQVIA Core Diabetes Model from a South Korean payer perspective in a simulated cohort based on the Korea National Health and Nutrition Examination Survey. A remaining lifetime horizon (up to 50 years), and a discount rate of 4.5% per annum were adopted. The willingness-to-pay threshold was KRW 47 million per quality-adjusted life year (QALY). Results: The use of rt-CGM resulted in an increase in quality-adjusted life expectancy of 0.490 QALYs and a KRW 13.3 million increase in costs compared with self-monitoring of blood glucose. The incremental cost-utility ratio in the base case analysis was KRW 27.1 million per QALY, below the willingness-to-pay threshold of KRW 47 million. Conclusions: rt-CGM is likely to be cost-effective versus self-monitoring of blood glucose in the management of patients with type 2 diabetes receiving basal insulin regimens in South Korea.